Travere reported Filspari net product sales up year-on-year, with contribution from its Tiopronin products. Learn why TVTX ...

Travere Therapeutics (TVTX) drew investor attention on 4 August 2026 after reporting second quarter results that combined ...

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Tuesday reported a loss of $34.8 million in its second quarter. The San Diego-based company said it had a loss of 37 cents per ...

(Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conf ...

Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation ...

Q2 reframed FILSPARI as a two-indication commercial story, with management emphasizing it was "the first quarter with FILSPARI commercially available across both IgA nephropathy and FSGS" (President, ...

3 Under-the-Radar Healthcare Companies Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record ...

Travere Therapeutics Inc. TVTX shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the biopharmaceutical ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics Inc. Annual cash flow by MarketWatch. View TVTX net cash flow, operating cash flow, operating expenses and cash dividends.

The now completed VISIONARY study marks another milestone in Otsuka’s rolling sBLA submission.